GREAT DEBATE: CLOPIDOGREL SHOULD NOW REPLACE ASPIRIN FOR LONG-TERM SECONDARY PREVENTION OF CORONARY ARTERY DISEASE

University of Glasgow, Cardiocentro Ticino Institute, University of Bern, Catholic University School of Medicine, University of Campania 'Luigi Vanvitelli', Imperial College London, East and North Hertfordshire NHS Trust, Royal Brompton Hospital

The article critically examines the historical preference for aspirin in long-term antiplatelet therapy for CAD, arguing that this preference is based more on legacy than on robust evidence. It highlights contemporary randomized trials and meta-analyses that support clopidogrel monotherapy as the preferred treatment strategy. The authors call for a reappraisal of current practices in light of new evidence, emphasizing the need for dedicated studies to validate these findings.